Literature DB >> 10539896

Molecular methods in the detection and identification of mycobacterial infections.

G L Woods1.   

Abstract

Nucleic acid amplification (NAA) tests for direct detection of Mycobacterium tuberculosis complex in respiratory specimens have the potential to provide a more rapid diagnosis of pulmonary tuberculosis (TB) than is currently possible by conventional stain, culture, and identification tests. Currently, 2 NAA tests-enhanced Amplified Mycobacterium Tuberculosis Direct (MTD) Test (Gen-Probe, Inc) and Amplicor Mycobacterium tuberculosis Test (Roche Molecular Systems, Inc)-have been approved by the Food and Drug Administration for testing respiratory specimens that are smear positive for acid-fast bacilli (AFB). This restriction to AFB smear-positive specimens was based on data from the initial clinical trials conducted to evaluate these products that showed low sensitivity (ie, 48%-53%) and less-than-optimal specificity (ie, 96%-99%) in AFB smear-negative specimens. Data from the clinical trial for the enhanced MTD test and from 2 subsequent studies, however, suggest that this version of the MTD test is a reliable tool for rapid diagnosis of pulmonary TB, regardless of the AFB smear result. Both NAA tests have been evaluated for diagnosis of extrapulmonary TB, and results were comparable to the results of tests performed with respiratory specimens. The NAA tests also appear to be reliable for rapid identification of M tuberculosis complex in positive broth cultures of all specimen types except blood. The impact of the NAA tests on patient outcome varies based on the AFB smear result. With smear-positive results, public health and hospital infection control resources are predominantly affected. With smear-negative results, however, the potential for affecting patient outcome is much greater. In patients with smear-negative results, the NAA test can result in earlier diagnosis of TB and subsequent initiation of therapy. Use of these tests also may eliminate the need for invasive diagnostic procedures, which are costly and pose an added risk to the patient, and they may allow earlier discharge of hospitalized patients.

Entities:  

Mesh:

Year:  1999        PMID: 10539896     DOI: 10.5858/1999-123-1002-MMITDA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  5 in total

1.  Molecular detection and identification of mycobacterium tuberculosis complex and four clinically important nontuberculous mycobacterial species in smear-negative clinical samples by the genotype mycobacteria direct test.

Authors:  Can Bicmen; Ayriz T Gunduz; Meral Coskun; Gunes Senol; A Kadri Cirak; Ayse Ozsoz
Journal:  J Clin Microbiol       Date:  2011-06-08       Impact factor: 5.948

2.  Rapid detection of smear-negative Mycobacterium tuberculosis by PCR and sequencing for rifampin resistance with DNA extracted directly from slides.

Authors:  M Patnaik; K Liegmann; J B Peter
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

3.  Tuberculosis of the breast.

Authors:  Salim Baharoon
Journal:  Ann Thorac Med       Date:  2008-07       Impact factor: 2.219

4.  A Case of False-Positive Mycobacterium tuberculosis Caused by Mycobacterium celatum.

Authors:  Edward Gildeh; Zaid Abdel-Rahman; Ruchira Sengupta; Laura Johnson
Journal:  Case Rep Infect Dis       Date:  2016-11-08

Review 5.  Molecular Diagnosis of Tuberculosis.

Authors:  Fariz Nurwidya; Diah Handayani; Erlina Burhan; Faisal Yunus
Journal:  Chonnam Med J       Date:  2018-01-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.